Form 4: Incyte Corp Executive Pablo J. Cagnoni Acquires Stock Options
SEC Form 4 Filing
Pablo J. Cagnoni, President of R&D at Incyte Corp, was granted stock options exercisable beginning January 17, 2025.
Summary
- Pablo J. Cagnoni, President of R&D at Incyte Corp, filed a Form 4 on January 21, 2025, reporting a transaction involving derivative securities.
- On January 17, 2025, Cagnoni acquired 40,289 employee stock options with an exercise price of $71.93.
- The options become exercisable in 37 installments, with 25% vesting on July 15, 2025, and the remainder vesting monthly over three years.
- Cagnoni also has a power of attorney designating Sheila A. Denton, Christiana Stamoulis, Elizabeth Feeney, and Thomas Tray to act on his behalf for Section 16 filings.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing related to executive compensation. The grant of stock options is generally viewed as a positive sign, aligning management's interests with shareholders, but it's not a major event.
Positives
- The acquisition of stock options aligns the executive's interests with those of the shareholders.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedule suggests a long-term commitment from the executive.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions in publicly traded companies. This filing indicates an executive's acquisition of stock options, which is a common form of compensation in the biotechnology industry.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options to incentivize their executives.
- The vesting schedule of these options, with a portion vesting after a certain period and the remainder vesting monthly over three years, is a typical arrangement.
Key Dates
| Date | Description |
|---|---|
| 2024-08-02 | Date of Power of Attorney execution. |
| 2025-01-17 | Date of stock option grant and start of vesting period. |
| 2025-01-21 | Date Form 4 was filed. |
| 2025-07-15 | Date of first vesting installment (25%). |
| 2035-01-16 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.